Historical references to the use of various forms of cannabis to treat the seizures in Epilepsy abound. From Sumerian runes, Arabic texts to modern day peer reviewed publications there have been clear and credible signals of therapeutic benefit. Translating this knowledge and understanding into a modern day pharmaceutical medicine that can be approved by the regulators represented a series of interesting challenges especially in terms of pharmaceutics, appropriate standards, analytical methodology and manufacturing processes. Developing a medicine from a highly purified preparation of a whole plant extract and then subjecting this to pre-clinical and clinical research created one of the most complex programmes in recent times. The approach to clinical evaluation and evidence generation in paediatric populations with rare and catastrophic epilepsies and associated behavioural phenotypes has yielded a novel methodology which may be appropriate for future medicines discovery and development.<br/>

Phytocannabinoids in the modern treatment of catastrophic epilepsies

2019 Fall National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.